This trial is investigating whether the drug alectinib is more effective than platinum-based chemotherapy in treating cancer, and is looking at the safety of both treatments. Participants will receive alectinib or platinum-based chemotherapy and then be followed up to see how their disease progresses.
1 Primary · 4 Secondary · Reporting Duration: From the date of randomization until death due to any cause up to approximately 8 years
2 Treatment Groups
1 of 2
1 of 2
257 Total Participants · 2 Treatment Groups
Primary Treatment: Alectnib · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are researchers presently recruiting study participants?
"Unfortunately, this specific clinical trial is no longer actively recruiting patients. The trial was initially posted on 8/16/2018 but was last edited on 8/10/2022. If you are interested in other trials, there are 1390 clinical trials for patients with carcinoma, non-small-cell lung and 1518 trials for Alectnib currently looking for patients." - Anonymous Online Contributor
How many people are approved to participate in this experiment?
"Unfortunately, this study is not currently recruiting patients. The trial began on August 16th, 2018 and concluded on August 10th, 2020. There are other ongoing studies that may be of interest; as of now, there are 1390 trials enrolling patients with non-small-cell lung carcinoma and 1518 trials enrolling patients for Alectinib." - Anonymous Online Contributor
What are Alectinib's common applications in medicine?
"Alectinib, while most commonly used to treat lymphoma, can also be used as a line of defense against non-hodgkin, recurrent cervical cancer, and locally advanced non-small cell lung cancer." - Anonymous Online Contributor
Do patients experience many side effects while taking Alectinib?
"Alectinib has received a score of 3 for safety. This is due to the Phase 3 status of the drug, meaning that there is both efficacy data as well as multiple rounds of safety data." - Anonymous Online Contributor